Lv42
626 积分 2024-04-29 加入
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
7小时前
已关闭
Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults: Implications for Clinicians
6天前
已完结
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
7天前
已完结
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
7天前
已完结
Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis
7天前
已完结
Prevalence and Treatment of Diabetes in China, 2013-2018
8天前
已完结
Increased Steroidogenic Acute Regulatory Protein (StAR) Contributes to Cholesterol-Induced β-cell Dysfunction
8天前
已完结
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
21天前
已完结
Relation Between Obesity and Type 2 Diabetes: Evolutionary Insights, Perspectives and Controversies
25天前
已完结
皖公网安备34019202002308
